REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions.
REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions - the RESURRECT Trial. A Pilot Proof-of-concept and Safety Study With the Paradise Denervation System
Royal Perth Hospital
75 participants
Oct 8, 2021
INTERVENTIONAL
Conditions
Summary
The is a non-randomized pilot trial, open-label evaluation of the physiologic response of native kidney denervation using the Paradise denervation system in CKD, End Stage Renal Disease (ESRD), and Heart failure (HF)
Eligibility
Inclusion Criteria6
- Both Male and female patients
- Ages between 18-75 years of age
- Individual is competent and willing to provide written, informed consent to participate in this clinical study with either
- CKD stage 3a/b or
- ESRD on stable renal replacement therapy or
- Mild to moderate heart failure with reduced ejection fraction
Exclusion Criteria10
- Ineligible anatomy
- Prior treatment with other devices for hypertension including but not limited to ROX Coupler (ROX Medical) , Mobius stent, and/or the CVRx (CVRx Inc) barostimulator device.
- Individual has experienced a myocardial infarction, unstable angina, or a cerebrovascular accident within 3 months of the screening visit.
- Documented history of chronic active inflammatory bowel disorders such as Crohn's disease or ulcerative colitis.
- Individual has clinically significant cardiac structural valvular disease, unless corrected by a properly functional prosthetic valve
- Individual has been admitted for inpatient hospitalization for decompensated HF in the previous month
- Female participants of childbearing potential must have a negative pregnancy test prior to treatment.
- Individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.
- Individual is currently enrolled in another investigational drug or device trial. Note: For the purpose of this protocol, participants involved in extended follow-up trials for products that were investigational but are currently commercially available are not considered enrolled in an investigational trial.
- Individual has a disease or condition (aside from CKD, ESRD, and HFrEF) that may limit their life expectancy to \< 1 year.
Interventions
All eligible participants receive ultrasound based renal denervation to both kidneys on all eligible vessels
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05703620